“We overcame several challenges in the first half of our fiscal year to deliver a strong second half, led by 6.5 percent organic revenue growth. We came in at the high end of both the revenue and EPS guidance we established at the start of the year,” said Omar Ishrak, CEO.
The cardiac and vascular unit reported sales growth of 10% to $3.14 billion. Sales in the Coronary & Structural Heart (CSH) unit rose 18.7% to $1.01 billion. Strong global demand for the new sensor-augmented insulin pump systems, boosted the total sales of diabetes unit by 26% to $645 million.
For fiscal 2019, the Fridley, Minnesota-based company expects organic revenue growth to be in the range of 4.0 to 4.5%. Revenue would be negatively affected by approximately $50-150 million. Non-GAAP EPS is expected to be in the range of $5.10 to $5.15.